NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP announces that class action lawsuits have
commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead
plaintiff have until the deadlines listed to petition the court and further details about the cases can be found at the links
provided. There is no cost or obligation to you.
Trevena, Inc. (NASDAQGS: TRVN)
Class Period: May 2, 2016 - October 9, 2018
Lead Plaintiff Deadline: December 10, 2018
Join the action: https://www.zlk.com/pslra-1/trevena-inc-loss-form?wire=3
Allegations: Trevena, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) during its
meetings with the FDA prior to the start of the Class Period, Trevena had been advised that the FDA did not agree with certain
aspects of the design of the Phase III clinical trial of Olinvo, including the proposed dosing, the proposed primary endpoint and
the proposed non-inferiority margin for comparing morphine to Olinvo; (b) unless Trevena demonstrated that Olinvo was at least
equally effective to morphine in treating post-operative pain in the Phase III clinical trial, the FDA would be unwilling to
consider any secondary benefits Olinvo might confer in terms of reduced opioid-related adverse effects ("ORAEs"); (c) the FDA
disagreed with how the safety data was being compiled in the Phase II clinical trial; (d) because the FDA did not agree with major
tenants of the design of the Phase III clinical trial, it was highly unlikely that the FDA would find the data obtained from that
clinical trial sufficient to support Trevena’s NDA; (e) because the Phase III clinical trial data being derived would not likely be
deemed sufficient to support the NDA for Olinvo, the Company would not be able to market Olinvo as soon as it was leading the
market to expect, if ever; and (f) as a result of the foregoing, the Company was not on track to achieve the commercial sales
revenues from Olinvo as soon as Defendants had led the market to expect during the Class Period, if ever.
To learn more about the Trevena, Inc. class action contact jlevi@levikorsinsky.com.
Nektar Therapeutics (NASDAQ: NKTR)
Class Period: November 11, 2017 - October 2, 2018
Lead Plaintiff Deadline: December 31, 2018
Join the action: https://www.zlk.com/pslra-1/nektar-therapeutics-loss-form?wire=3
Allegations: During the class period, Nektar Therapeutics made materially false and/or misleading statements and/or failed to
disclose that: (1) prior studies which attempted to pegylate IL-2 failed; (2) the extended half-life of the Company's lead I-O
candidate, NKTR-214, was unlikely to result in efficacy and created additional high-dosing safety concerns; (3) NKTR-214 was less
effective than IL-2 alone; (4) the combination of NKTR-214 with nivolumab has yet to demonstrate significant positive results; and
(5) as a result, Nektar’s public statements as set forth above were materially false and misleading at all relevant times.
To learn more about the Nektar Therapeutics class action contact jlevi@levikorsinsky.com.
Synchrony Financial (NYSE: SYF)
Class Period: October 21, 2016 - November 1, 2018
Lead Plaintiff Deadline: January 2, 2019
Join the action: https://www.zlk.com/pslra-1/synchrony-financial-loss-form?wire=3
The complaint alleges that during the Class Period, Synchrony falsely represented that its consistent and disciplined
underwriting practices had led to a higher quality loan portfolio than those of its competitors. In truth, Synchrony relaxed its
underwriting standards and increasingly offered private-label credit cards to riskier borrowers to sustain growth. The truth about
Synchrony's credit standards began to be revealed on April 28, 2017, when the Company announced disappointing first quarter 2017
earnings driven by poor loan performance. Following this disclosure, the Company represented that it had tightened credit
standards, but falsely characterized those underwriting changes as modest. In fact, the Company had made significant modifications
to its underwriting policies, but concealed that these modifications were damaging its relationships with its retail partners,
including Walmart.
To learn more about the Synchrony Financial class action contact jlevi@levikorsinsky.com.
You have until the lead plaintiff deadlines to request the court appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys
have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of
dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
